Current treatment of chronic HBV infection: An Asian-Pacific perspective

被引：1
作者：
Liaw Y.-F. [1 ]
Chien R.-N. [1 ]
机构：
[1] Chang Gung Memorial Hospital and University, Taipei
来源：
Current Hepatitis Reports | 2009年 / 8卷 / 4期
关键词：
Chronic Hepatitis; Entecavir; HBeAg Seroconversion; Adefovir Dipivoxil; HBeAg Seroconversion Rate;
D O I：
10.1007/s11901-009-0022-x
中图分类号：
学科分类号：
摘要：
Chronic hepatitis B virus (HBV) infection is a major global health problem with potential adverse sequelae including liver cirrhosis and hepatocellular carcinoma. Of more than 350 million chronic HBV carriers, 75% reside in the Asian-Pacific region, where most countries have low-income economies. Better understanding of the natural history and immunopathogenesis of chronic HBV infection and the invention of powerful antiviral agents have improved the therapeutic strategy. Guidelines issued by major liver associations are basically similar. However, each country in the Asian-Pacific region has specific problems. Because cost is a main concern, drugs with low genetic barrier to resistance are still widely used in these countries. Modifications needed to accommodate specific situations and problems include more stringent indications for drug therapy, starting therapy with the least expensive drug, and defining stopping rules even for hepatitis B e antigen-negative patients. © 2009 Springer Science+Business Media, LLC.
引用
收藏
页码：154 / 160
页数：6
相关论文
共 55 条
  • [51] Flink H.J., Van Zonneveld M., Hansen B.E., De Man R.A., Schalm S.W., Janssen H.L.A., Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype, American Journal of Gastroenterology, 101, 2, pp. 297-303, (2006)
  • [52] Liaw Y.F., Management of patients with chronic hepatitis B and cirrhosis, Curr Hepatitis Rep, 6, pp. 161-165, (2007)
  • [53] Yuen M.F., Seto W.K., Chow D.H.F., Et al., Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease, Antivir Ther, 12, pp. 1295-1303, (2007)
  • [54] Matsumoto A., Tanaka E., Rokuhara A., Kiyosawa K., Kumada H., Omata M., Okita K., Hayashi N., Okanoue T., Iino S., Tanikawa K., Watanabe S., Kawada S., Yokosuka O., Hino K., Ishii H., Kumada H., Toda G., Arakawa Y., Enomoto N., Kiyosawa K., Ichida T., Kamimura T., Mizogami M., Kakumu S., Moriwaki H., Kaneko S., Okanoue T., Hayashi N., Kudo M., Shiratori Y., Yamada G., Chayama K., Okita K., Kuriyama S., Onji M., Ohnishi S., Sata M., Fujiyama S., Sasaki H., Tsubouchi H., Ishibashi H., Yatsuhashi
  • [55] Chien R.-N., Yeh C.-T., Tsai S.-L., Chu C.-M., Liaw Y.-F., Determinants for Sustained HBeAg Response to Lamivudine Therapy, Hepatology, 38, 5, pp. 1267-1273, (2003)
123456